This a competitive renewal application for the Cancer Center Support Grant (CCSG) of Roswell Park Cancer Institute (RPCI) for the grant period 2000-2005. This grant is entering its 25th year of uninterrupted funding. Over the last three years RPCI has achieved tremendous new changes in its governance, increased Institutional Commitment to staff recruitment (38 new faculty within the next three years), major renovation of program facilities, expanded philanthropic funding, reorganization of clinical and scientific departments, established interactive scientific and clinical translational programs, strengthened its administrative infrastructure, and enhanced its programmatic relationship with the University at Buffalo. Under the leadership of Dr. David Hohn, President and CEO, RPCI is well-positioned to take advantage of new opportunities and challenges. The Center seeks a significant increase in CCSG funding to match its expanded Institutional commitment. The total request of $3,039,144 will support six scientific programs (Therapeutics, Biophysical Therapies, Immunology, Mouse Molecular Genetics, Cancer Genetics), two disease-oriented programs (Gastrointestinal Oncology, Breast Cancer Research), a Cancer Prevention and Control Program, fourteen shared resources and three clinical support units. The requested support has increased from approximately $1.5 million to $3.0 million. The increase is distributed as follows: New shared resources (25%), increased utilization of existing shared resources. (17%), expansion of shared resources (11%), developmental funds), and requests for salary of senior and program leadership (29%). The funds will be used to support 182 CCSG full members have peer-reviewed funding. With the new leadership, improved environment for basic and translational research, and an increased Institute financial commitment to program development, RPCI is poised to make significant new advances in prevention, early detection, diagnosis and treatment of cancer over the next five years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016056-26S2
Application #
6755873
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1983-12-01
Project End
2003-07-31
Budget Start
2001-05-07
Budget End
2003-07-31
Support Year
26
Fiscal Year
2003
Total Cost
$306,439
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Sheffer, Christine E; Miller, Austin; Bickel, Warren K et al. (2018) The treasure of now and an uncertain future: Delay discounting and health behaviors among cancer survivors. Cancer 124:4711-4719
Nesher, Elimelech; Safina, Alfiya; Aljahdali, Ieman et al. (2018) Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs. Cancer Res 78:1431-1443
Verma, Aparajita; Rich, Laurie J; Vincent-Chong, Vui King et al. (2018) Visualizing the effects of metformin on tumor growth, vascularity, and metabolism in head and neck cancer. J Oral Pathol Med 47:484-491
Buas, Matthew F; Li, Christopher I; Anderson, Garnet L et al. (2018) Recommendation to use exact P-values in biomarker discovery research in place of approximate P-values. Cancer Epidemiol 56:83-89
Szender, J Brian; Kaur, Jasmine; Clayback, Katherine et al. (2018) Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer. Int J Gynecol Cancer 28:26-33
Azad, T; Janse van Rensburg, H J; Lightbody, E D et al. (2018) A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis. Nat Commun 9:1061
Ling, Xiang; Wu, Wenjie; Fan, Chuandong et al. (2018) An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer. J Exp Clin Cancer Res 37:240
Chung, Sejin; Vail, Paris J; Witkiewicz, Agnieszka K et al. (2018) Coordinately targeting cell cycle checkpoint functions in integrated models of pancreatic cancer. Clin Cancer Res :
Eng, Diana G; Kaverina, Natalya V; Schneider, Remington R S et al. (2018) Detection of renin lineage cell transdifferentiation to podocytes in the kidney glomerulus with dual lineage tracing. Kidney Int 93:1240-1246
Hsu, Alice H; Lum, Michelle A; Shim, Kang-Sup et al. (2018) Crosstalk between PKC? and PI3K/AKT Signaling Is Tumor Suppressive in the Endometrium. Cell Rep 24:655-669

Showing the most recent 10 out of 1555 publications